<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902020000300237</article-id>
<article-id pub-id-type="doi">10.29262/ram.v67i3.745</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eficacia y seguridad de dos esquemas de desensibilización a trimetoprima con sulfametoxazol en pacientes positivos a VIH]]></article-title>
<article-title xml:lang="en"><![CDATA[The efficacy and safety of two schemes of desensitization to trimethoprim-sulfamethoxazole in HIV-positive patients]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Morales]]></surname>
<given-names><![CDATA[María del Rocío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mancilla-Hernández]]></surname>
<given-names><![CDATA[Eleazar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Secretaría de Salud Hospital General de Puebla Dr. Eduardo Vázquez Navarro ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de Investigación en el Área de la Salud A.C.  ]]></institution>
<addr-line><![CDATA[ Puebla]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<volume>67</volume>
<numero>3</numero>
<fpage>237</fpage>
<lpage>244</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902020000300237&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902020000300237&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902020000300237&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes:  La trimetoprima con sulfametoxazol (TMP-SMX) es el fármaco de elección para la profilaxis de comorbilidades asociadas al síndrome de inmunodeficiencia adquirida.  Objetivo:  Comparar la eficacia y seguridad de dos esquemas de desensibilización a TMP-SMX en pacientes positivos al virus de la inmunodeficiencia humana (VIH).  Métodos: Estudio de marzo de 2018 a octubre de 2019. Se incluyeron pacientes VIH-positivos con alguna reacción cutánea adversa debida a TMT-SMX; 15 recibieron el esquema 1 de desensibilización de 10 días de duración y cinco, el esquema 2 de seis horas de duración.  Resultados:  El promedio de edad fue de 27.4 ± 5.7 y 33.6 ± 8 años en los pacientes que recibieron los esquemas 1 y 2, respectivamente. En estado basal, las variables demográficas, clínicas e inmunológicas no mostraron diferencias significativas entre los grupos (p &gt; 0.05). Con ambos esquemas se obtuvo una eficacia de 100 %. Solo tres pacientes que recibieron el esquema 1 presentaron rash y prurito, pero no se suspendió el procedimiento; se regresó a la dosis previa tolerada y posteriormente se continuó la desensibilización.  Conclusiones:  Los dos esquemas de desensibilización a TMP-SMX mostraron eficacia y seguridad en los pacientes VIH-positivos, en quienes son frecuentes las reacciones adversas a esos medicamentos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background:  Trimethoprim with sulfamethoxazole (TMP-SMX) is the drug of choice for the prophylaxis of AIDS-associated comorbidities.  Objective:  To compare the efficacy and safety of two schemes of desensitization to TMP-SMX in HIV-positive patients.  Methods:  A study was conducted from March 2018 to October 2019; it included HIV-positive patients who presented an adverse skin reaction to TMP-SMX; fifteen of them received desensitization scheme 1, which lasted ten days, and five patients received scheme 2, which lasted six hours.  Results:  The average age of the patients who received scheme 1 was of 27.4 ± 5.7 years, while the average age of patients who received scheme 2 was of 33.6 ± 8 years. At baseline, the demographic, clinical, and immunological variables did not show significant differences between both groups (p&gt; 0.05). In both groups, an efficacy of 100% was obtained and, in terms of safety, only three patients in group 1 presented rash and pruritus, however, the procedure was not suspended; the previous tolerated dose was resumed and, subsequently, the desensitization procedure continued.  Conclusions:  Both schemes of desensitization to TMP-SMX showed efficacy and safety in HIV-positive patients, who frequently present adverse reactions to these medications.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Reacciones adversas a medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Trimetoprima-sulfametoxazol]]></kwd>
<kwd lng="es"><![CDATA[Desensibilización]]></kwd>
<kwd lng="es"><![CDATA[Infección por virus de la inmunodeficiencia humana]]></kwd>
<kwd lng="en"><![CDATA[Adverse drug reaction]]></kwd>
<kwd lng="en"><![CDATA[Trimethoprim-sulfamethoxazole]]></kwd>
<kwd lng="en"><![CDATA[Desensitization]]></kwd>
<kwd lng="en"><![CDATA[Infection by human immunodeficiency virus]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[VIH-SIDA]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Suiza ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrillo-Maravilla]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Villegas-Jiménez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El descubrimiento del VIH en los albores de la epidemia del sida]]></article-title>
<source><![CDATA[Rev Invest Clin.]]></source>
<year>2004</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>130-3</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="book">
<collab>Vigilancia epidemiológica de casos de VIH/SIDA en México</collab>
<source><![CDATA[Registro Nacional de Casos de SIDA]]></source>
<year>2016</year>
<publisher-name><![CDATA[Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuluaga]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protocolo de estudio y manejo de infección por Pneumocystis jirovecii]]></article-title>
<source><![CDATA[Infectio]]></source>
<year>2012</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>129-31</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Warrington]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug allergy: causes and desensitization]]></article-title>
<source><![CDATA[Hum Vaccin Immunother]]></source>
<year>2012</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1513-24</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solensky]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug desensitization]]></article-title>
<source><![CDATA[Immunol Allergy Clin North Am.]]></source>
<year>2004</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>425-43</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torgovnick]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arsura]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desensitization to sulfonamides in patients with HIV infection]]></article-title>
<source><![CDATA[Am J Med.]]></source>
<year>1990</year>
<volume>88</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>548-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Absar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Daneshvar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Beall]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients]]></article-title>
<source><![CDATA[J Allergy Clin Immunol.]]></source>
<year>1994</year>
<volume>98</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1001-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pyle]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Butterfield]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yolcheck]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Podjasek]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Rank]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[JTC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract.]]></source>
<year>2014</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>52-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoosen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mosam]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dlova]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Grayson]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update on adverse cutaneous drug reactions in HIV/AIDS]]></article-title>
<source><![CDATA[Dermatopathology]]></source>
<year>2019</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>111-25</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoshizawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yasuaka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kikuchi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Honda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gatanaga]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tachikawa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol.]]></source>
<year>2000</year>
<volume>85</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>241-4</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Demoly]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Messaad]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sahla]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fabre]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Faucherre]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
<name>
<surname><![CDATA[André]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Six-hour trimethoprim-sulfamethoxazole- graded challenge in HIV-infected patients]]></article-title>
<source><![CDATA[J Allergy Clin Immunol.]]></source>
<year>1998</year>
<volume>102</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1033-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Penny]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[DA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of rechallenge with low-dose trimethoprim sulfamethoxazole in previously hypersensitive HIV-infected patients]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>1993</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-71</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cribb]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Trepanier]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis]]></article-title>
<source><![CDATA[Adverse Drug React Toxicol Rev.]]></source>
<year>1996</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-50</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belchi-Hernández]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Parra]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol.]]></source>
<year>1996</year>
<volume>76</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>355-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
